AR066649A1 - Reovirus mutantes y metodos de elaboracion y uso de los mismos - Google Patents

Reovirus mutantes y metodos de elaboracion y uso de los mismos

Info

Publication number
AR066649A1
AR066649A1 ARP080102139A ARP080102139A AR066649A1 AR 066649 A1 AR066649 A1 AR 066649A1 AR P080102139 A ARP080102139 A AR P080102139A AR P080102139 A ARP080102139 A AR P080102139A AR 066649 A1 AR066649 A1 AR 066649A1
Authority
AR
Argentina
Prior art keywords
reovirus
methods
elaboration
mutants
same
Prior art date
Application number
ARP080102139A
Other languages
English (en)
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of AR066649A1 publication Critical patent/AR066649A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un reovirus mutante, CARACTERIZADO PORQUE dicho reovirus mutante comprende una primera mutacion, en donde dicha primera mutacion reduce la expresion de un polipéptido sigma3, elimina esencialmente la expresion de un polipéptido sigma3 o da como resultado la ausencia de un polipéptido sigma3 funcional. Reivindicacion 9: Una partícula subviral infecciosa (ISVP) de reovirus, CARACTERIZADA PORQUE fue manipulada genéticamente. También se proveen composiciones que incluyen reovirus mutantes y métodos de uso de dichos reovirus mutantes.
ARP080102139A 2007-05-21 2008-05-20 Reovirus mutantes y metodos de elaboracion y uso de los mismos AR066649A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93925507P 2007-05-21 2007-05-21

Publications (1)

Publication Number Publication Date
AR066649A1 true AR066649A1 (es) 2009-09-02

Family

ID=40031362

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102139A AR066649A1 (es) 2007-05-21 2008-05-20 Reovirus mutantes y metodos de elaboracion y uso de los mismos

Country Status (15)

Country Link
US (1) US20080292594A1 (es)
EP (1) EP2150613B1 (es)
JP (1) JP2010527593A (es)
CN (2) CN101679953A (es)
AR (1) AR066649A1 (es)
AU (1) AU2008253505B2 (es)
CA (1) CA2680661C (es)
DK (1) DK2150613T3 (es)
ES (1) ES2611455T3 (es)
HK (1) HK1136006A1 (es)
IL (1) IL200690A (es)
MX (1) MX2009012420A (es)
TW (1) TW200909581A (es)
WO (1) WO2008141448A1 (es)
ZA (1) ZA200907017B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720624D0 (en) * 2007-10-20 2007-11-28 Academisch Ziekenhuis Leiden Viral Modification
AU2008316276A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
EP2296679A4 (en) * 2008-05-27 2012-03-21 Oncolytics Biotech Inc SUPPRESSION OF PRODUCTION OF PRO-INFLAMMATORY CYTOKINES DURING ONCOLYTIC REOVIRUS THERAPY
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
TW201233803A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
JP6034798B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
ES2796950T3 (es) 2013-11-15 2020-11-30 Oncolytics Biotech Inc Virus oncolíticos y regímenes reforzados para tratamiento de cáncer
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis
KR20210098202A (ko) * 2020-01-31 2021-08-10 바이로큐어 주식회사 레오바이러스를 유효성분으로 포함하는 대장염의 예방 또는 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
PT1098961E (pt) * 1998-06-12 2008-04-23 Mount Sinai School Of Med Of T Vírus atenuados produzidos por engenharia genética indutores de interferão
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
DE60142485D1 (de) * 2000-11-09 2010-08-12 Oncolytics Biotech Inc Verfahren zur Beurteilung von zellulären proliferativen Erkrankungen
CA2437962C (en) * 2001-03-16 2005-11-15 Oncolytics Biotech Inc. Method of extracting virus from cell culture
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
US10260049B2 (en) * 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus

Also Published As

Publication number Publication date
IL200690A0 (en) 2011-08-01
DK2150613T3 (en) 2017-01-30
EP2150613B1 (en) 2016-10-19
ZA200907017B (en) 2010-12-29
CN101679953A (zh) 2010-03-24
TW200909581A (en) 2009-03-01
CA2680661A1 (en) 2008-11-27
IL200690A (en) 2014-02-27
MX2009012420A (es) 2009-12-09
ES2611455T3 (es) 2017-05-09
WO2008141448A1 (en) 2008-11-27
US20080292594A1 (en) 2008-11-27
HK1136006A1 (zh) 2010-06-18
JP2010527593A (ja) 2010-08-19
EP2150613A4 (en) 2011-01-19
EP2150613A1 (en) 2010-02-10
AU2008253505B2 (en) 2014-09-04
AU2008253505A1 (en) 2008-11-27
CN104195115A (zh) 2014-12-10
CA2680661C (en) 2018-05-29

Similar Documents

Publication Publication Date Title
AR066649A1 (es) Reovirus mutantes y metodos de elaboracion y uso de los mismos
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
WO2018226732A8 (en) MULTIBIOTIC AGENTS AND METHODS OF USE THEREOF
ATE553792T1 (de) Medizinische vorrichtungen mit verbundstoffen
MXPA05013973A (es) Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos.
AR064725A1 (es) Profilaxis y tratamiento del complejo respiratorio porcino (prdc). uso
DE60143517D1 (de) Wiederherstellung der gelenken mit mesenchymalen stammzellen
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
HN2005029978A (es) Formulaciones
AU2008326599A8 (en) Modulation of the immune response
WO2002009650A3 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
NO20085396L (no) Antistoffer og immunkonjugater, og anvendelser derav
SG127836A1 (en) Light diffusing films, methods of making the same,and articles using the same
ECSP088831A (es) Anticuerpos anti-tat226 e inmunoconjugados
AR054937A1 (es) Goma de mascar biodegradable
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
BR112021019349A2 (pt) Células-tronco preparadas altamente funcionais
ECSP088203A (es) Dispersiones amorfas sólidas
TW200703884A (en) Miller-compensated amplifier
WO2002013760A3 (en) Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
SV2006002220A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios ref. p-sv-78.836/cd
MX2008011844A (es) Formulaciones de sitaxsentano de sodio.
WO2005086938A3 (en) Artificial mutation controls for diagnostic testing
WO2008120201A3 (en) An isolated population of cells and methods of generating and using same

Legal Events

Date Code Title Description
FB Suspension of granting procedure